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In the past few decades, a major shift in the local management of breast cancer has occurred: mastectomy was replaced by breast-conserving surgery (BCS) followed by post-operative whole breast radiotherapy (WBRT).
1,2 Solid evidence from randomised trials supports that the combined treatment has equivalent results to mastectomy in terms of local control and survival rates. 1, 2 This is a paradigm of a changing standard of care in favour of a new treatment that provides the same clinical results in terms of cure rates, decreased side effects, organsparing and the prospect of a better quality of life.
The role of radiotherapy after breast cancer surgery is to minimise the local relapse risk. Post-operative radiotherapy includes the irradiation of the whole remaining breast with about 50Gy delivered daily for five to six weeks with an additional local boost dose to the tumour bed, when appropriate. 3 Recently, a new concept of accelerated partial breast irradiation (APBI), which consists of the irradiation of a limited volume of mammary gland immediately surrounding the tumour bed, has been investigated as an alternative to WBRT.
Rationale for and Potential Advantages of Partial Breast Irradiation
The rationale for the use of PBI was based on clinical [4] [5] [6] [7] and pathological 8,9 observations of long-term studies reporting that the majority of breast tumour recurrences occur in proximity to the lumpectomy cavity. In addition, breast cancer relapses outside of the original tumour bed appear to occur with the same frequency following lumpectomy regardless of whether or not adjuvant whole breast irradiation is delivered. 6, 10 Consequently, WBRT may not be necessary since most ipsilateral breast tumour relapses occur in the vicinity of the primary tumour and radiotherapy does not seem to prevent other quadrant relapses.
Furthermore, PBI offers increased convenience due to a shorter duration of radiation therapy (five to seven days versus six weeks). This significant shortening of the treatment time is extremely important in order to overcome socioeconomic barriers that negatively affect patient compliance with radiotherapy. Indeed, a high rate of breast cancer patients tend to choose mastectomy instead of lumpectomy plus radiotherapy due to limited financial means, and/or long travel distances to the radiation facilities, and/or lack of time and/or due to their advanced age. [11] [12] [13] Moreover, in countries with limited radiotherapy institutions, patients treated with BCS may wait a prolonged time before beginning radiotherapy. Consequently, there is a delay in the initiation of systemic adjuvant chemotherapy, which may affect overall survival. Treatment is delivered immediately in the lumpectomy cavity using a high-dose source, which is inserted into the centre of the balloon.
The method is simple, with a short learning curve. 22 Conversely, the limitations of the technique are that the target volume is standardised without allowing individual conformation and the therapeutic range is only 10mm. 17 Additionally, the distance between the balloon and the skin appears to be the most important factor for achieving optimal cosmetic results. 23, 24 Moreover, catheters can be a source of discomfort and potentially promote bleeding, infections and late damage such as fibrosis and telangiectasia.
Intraoperative radiotherapy (IORT) consists of single-fraction treatment targeted at the tumour bed during the surgical procedure, immediately after the removal of the tumour mass. Two modalities of IORT have been described using either electron, as developed in Milan, 25 or photon beams (based on 'soft' X-rays of 50kV) developed by the University College of London. 26 As this irradiation is performed during the same surgical procedure, there is no need for future hospitalisation and transportation of patients. Moreover, the application of a high-dose precisely targeted to a limited volume can be performed while sparing the surrounding tissues. 17 The major flaw of this technique is the lack of definite pathological data regarding resection margins, histological features and axillary nodal status at the time of radiation therapy.
A recent consensus statement from the American Society for Radiation Oncology (ASTRO) concluded that there are insufficient clinical and dosimetric data to determine the optimal technique for APBI delivery.
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Current Randomised Evidence
To date, five randomised trials have been published comparing PBI and WBRT in patients with early breast cancer. Four of them [28] [29] [30] 32 reported data on locoregional recurrences and overall survival, while the fifth study 31 was a preliminary acute toxicity analysis of an ongoing randomised trial. A meta-analysis 33 of three completed randomised studies [28] [29] [30] has been recently published while the fourth study 32 was presented after the completion of the meta-analysis and was not included. in 10 fractions in 10 days). In this study, the limited field irradiation was significantly associated with higher local and regional recurrences, while there were no differences in terms of overall survival and distant metastases between the two treatment arms. These disappointing results should be interpreted with caution due to the old radiation technique used in the study, the poor quality control, the inadequate axillary and systemic management and the incomplete pathological examination. 35 In addition, a single field size was used for all patients in the limited-field arm irrespective of the tumour dimensions or other characteristics, which could have resulted in several instances of 'geographical miss'. The lack of appropriate patient selection criteria was highlighted when the results were analysed according to the type of primary tumour and it was found that limited-field radiotherapy was inadequate only for patients with infiltrating lobular cancers or cancers with an extensive intra-ductal component.
The second study was performed during 1986-1990 by the Yorkshire Breast Cancer Group. 30 In this study, 174 patients, irrespective of nodal status, were randomised to receive either WBRT or irradiation only in the tumour bed. In this study, a higher risk of locoregional recurrences was demonstrated. However, there were uncertainties on target-volume definition, the irradiation technology used was inadequate, more patients in the tumour-bed-only irradiation arm had axillary node positive disease and the study did not reach its target on participants due to a low accrual rate.
The first well-designed randomised phase III trial was performed by the National Institute of Oncology in Hungary. 28, 36, 37 In this study, 258 patients with T1, N0-1mi, grade 1-2, non-lobular breast cancer undergoing BCS were randomised to either WBRT or APBI (high-dose-rate interstitial brachytherapy or limited-field electron-beam radiotherapy). At the median follow-up of 60 months there were no significant differences in locoregional recurrences or overall survival. Regarding toxicity, there were no significant differences between the two treatment arms in terms of incidence of fat necrosis and late radiation side effects. 37 Patients with APBI had a better cosmetic result compared with WBRT. 37 The Hungarian study is the only randomised trial that analysed the cosmetic results and the late side-effects of APBI.
A preliminary analysis of an Italian study including 259 patients who were randomised to receive either WBRT or APBI demonstrated that APBI has a very low acute skin toxicity.
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A meta-analysis of the three above-mentioned phase III randomised controlled studies comparing partial breast irradiation with whole breast-radiation therapy was recently presented. 33 The results of the meta-analysis are encouraging about the future role of APBI since it does not seem to jeopardise overall survival in patients with early breast cancer. The higher locoregional recurrence risk in the APBI arm needs to be considered with caution due to biases of the eligible studies, [28] [29] [30] as discussed above.
Nevertheless, the limited available randomised data (only three eligible trials), the variety of the PBI techniques used, the poor methodological quality of the two included trials 29, 30 and the relatively shorter median follow-up (five years) in two trials 28, 30 compared with the median time needed in order to demonstrate the impact on mortality (seven to eight years) 38 are considerable limitations of the meta-analysis.
Recently, the results of the Targeted Intraoperative Radiotherapy 
Concerns Regarding Partial Breast Irradiation
Besides the above-mentioned theoretical advantages of APBI, there are also data from studies that raise concerns in terms of the rationale for 
Conclusion
PBI is a new technology that offers potential advantages compared with WBRT. The most valid concern regarding PBI as a new treatment modality in oncology is its oncological safety. Although limited, current randomised evidence supports that this new technology is a safe treatment modality as it does not seem to jeopardise survival compared with standard WBRT. Nevertheless, this radiation-delivering technique is unlikely to replace WBRT as the 'gold standard' treatment for all early breast cancer patients. Ongoing large phase III randomised trials will identify the subgroups of patients who will benefit from PBI. Until then, PBI methods remain investigational and should be performed only in patients enrolled in controlled clinical trials. n
